Handling of missing data in long-term clinical trials: a case study

被引:0
|
作者
Janssens, Mark [1 ]
Molenberghs, Geert [2 ,3 ]
Kerstens, Rene [1 ]
机构
[1] Shire Movetis NV, B-2300 Turnhout, Belgium
[2] Univ Hasselt, I BioStat, B-3590 Diepenbeek, Belgium
[3] Kaholieke Univ Leuven, B-3590 Diepenbeek, Belgium
关键词
longitudinal data; missing data; sensitivity analysis; pattern-mixture models; PATTERN-MIXTURE MODELS; SEVERE CHRONIC CONSTIPATION; OF-LIFE QUESTIONNAIRE; PATIENT ASSESSMENT; PRUCALOPRIDE;
D O I
10.1002/pst.1532
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Missing data in clinical trials is a well-known problem, and the classical statistical methods used can be overly simple. This case study shows how well-established missing data theory can be applied to efficacy data collected in a long-term open-label trial with a discontinuation rate of almost 50%. Satisfaction with treatment in chronically constipated patients was the efficacy measure assessed at baseline and every 3?months postbaseline. The improvement in treatment satisfaction from baseline was originally analyzed with a paired t-test ignoring missing data and discarding the correlation structure of the longitudinal?data. As the original analysis started from missing completely at random assumptions regarding the missing data process, the satisfaction data were re-examined, and several missing at random (MAR) and missing not at random (MNAR)?techniques resulted in adjusted estimate for the improvement in satisfaction over 12?months. Throughout the different sensitivity analyses, the effect sizes remained significant and clinically relevant. Thus, even for an open-label trial design, sensitivity analysis, with different assumptions for the nature of dropouts (MAR or MNAR) and with different classes of models (selection, pattern-mixture, or multiple imputation models), has been found useful and provides evidence towards the robustness of the original analyses; additional sensitivity analyses could be undertaken to further qualify robustness. Copyright (c) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:442 / 448
页数:7
相关论文
共 50 条
  • [1] Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study
    Liu, M
    Wei, L
    Zhang, J
    [J]. PHARMACEUTICAL STATISTICS, 2006, 5 (01) : 7 - 18
  • [2] Handling missing data in clinical trials: An overview
    Myers, WR
    [J]. DRUG INFORMATION JOURNAL, 2000, 34 (02): : 525 - 533
  • [3] Handling Missing Data in Clinical Trials: An Overview
    William R. Myers
    [J]. Drug information journal : DIJ / Drug Information Association, 2000, 34 (2): : 525 - 533
  • [4] Handling missing data issues in clinical trials for rheumatic diseases
    Wong, Weng Kee
    Boscardin, W. J.
    Postlethwaite, A. E.
    Furst, D. E.
    [J]. CONTEMPORARY CLINICAL TRIALS, 2011, 32 (01) : 1 - 9
  • [5] A review of the handling of missing longitudinal outcome data in clinical trials
    Matthew Powney
    Paula Williamson
    Jamie Kirkham
    Ruwanthi Kolamunnage-Dona
    [J]. Trials, 15
  • [6] Commentary: Indefensible Methods of Handling Missing Data in Clinical Trials
    Arndt, Stephan
    [J]. ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2013, 37 (12) : 1997 - 1998
  • [7] AN OVERVIEW OF PRACTICAL APPROACHES FOR HANDLING MISSING DATA IN CLINICAL TRIALS
    DeSouza, Cynthia M.
    Legedza, Anna T. R.
    Sankoh, Abdul J.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2009, 19 (06) : 1055 - 1073
  • [8] A review of the handling of missing longitudinal outcome data in clinical trials
    Powney, Matthew
    Williamson, Paula
    Kirkham, Jamie
    Kolamunnage-Dona, Ruwanthi
    [J]. TRIALS, 2014, 15
  • [9] MISSING DATA HANDLING METHODS IN MEDICAL DEVICE CLINICAL TRIALS
    Yan, Xu
    Lee, Shiowjen
    Li, Ning
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2009, 19 (06) : 1085 - 1098
  • [10] AN AID TO DATA MONITORING IN LONG-TERM CLINICAL-TRIALS
    HALPERIN, M
    LAN, KKG
    WARE, JH
    JOHNSON, NJ
    DEMETS, DL
    [J]. CONTROLLED CLINICAL TRIALS, 1982, 3 (04): : 311 - 323